Last $10.67 USD
Change Today +0.32 / 3.09%
Volume 389.7K
RMTI On Other Exchanges
Symbol
Exchange
RMTI is not on other exchanges.
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

rockwell medical inc (RMTI) Snapshot

Open
$10.35
Previous Close
$10.35
Day High
$10.80
Day Low
$10.01
52 Week High
11/22/13 - $15.85
52 Week Low
05/15/13 - $3.25
Market Cap
435.0M
Average Volume 10 Days
420.6K
EPS TTM
$-1.65
Shares Outstanding
40.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROCKWELL MEDICAL INC (RMTI)

Related News

No related news articles were found.

rockwell medical inc (RMTI) Related Businessweek News

No Related Businessweek News Found

rockwell medical inc (RMTI) Details

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease (CKD), iron deficiency, secondary hyperparathyroidism, and hemodialysis. The company’s products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. Its lead drug candidates include Triferic, which is in late-stage clinical development for the treatment of iron replacement in dialysis patients; and Calcitriol, a generic active vitamin D for the treatment of secondary hyperparathyroidism in dialysis patients. The company also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid, Renal Pure liquid acid concentrate, dry acid concentrate mixing system, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Rockwell Medical, Inc. sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. The company was founded in 1995 and is based in Wixom, Michigan.

286 Employees
Last Reported Date: 03/7/14
Founded in 1995

rockwell medical inc (RMTI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $681.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $406.3K
Chief Medical Officer
Total Annual Compensation: $262.1K
Chief Scientific Officer and Member of Scient...
Total Annual Compensation: $478.8K
Compensation as of Fiscal Year 2012.

rockwell medical inc (RMTI) Key Developments

Rockwell Medical, Inc. Submits New Drug Application for Triferic for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis

Rockwell Medical, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Triferic (soluble ferric pyrophosphate citrate), the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. The NDA submission is based primarily on the datasets derived from the Triferic Phase 3 registration study program, and includes efficacy and safety data from additional studies. Triferic is a unique iron compound that is delivered to the hemodialysis patient via dialysate, replacing the 5-7 mg of iron that is lost during every dialysis treatment. Triferic is introduced into the sodium bicarbonate concentrate on-site at the dialysis clinic, which is subsequently mixed into dialysate. Once in the dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to apo-transferrin and is taken to the bone marrow, similar to how dietary iron is processed in the human body. In completed clinical trials to date, Triferic has demonstrated that it can safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose.

Rockwell Medical, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Rockwell Medical, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported a loss of $8.3 million or $0.21 per basic and diluted share, a 39% reduction compared to $13.7 million or $0.66 per basic and diluted share in the fourth quarter of 2012. Sales were $13,964,624 compared to $12,999,846 for the last year. Operating loss was $7,529,010 compared to $13,684,417 for the last year. Loss before income taxes was $8,332,105 compared to $13,673,488 for the last year. For the year, the company reported a loss of $48.8 million or $1.48 per basic and diluted share, a 9.7% reduction compared to $54.0 million or $2.65 per basic and diluted share in 2012. Sales were $52,379,543 compared to $49,842,392 for the last year. Operating loss was $47,059,266 compared to $54,262,082 for the last year. Loss before income taxes was $48,783,312 compared to $54,021,515 for the last year. Cash used in operating activities was $50,664,953 compared to $30,746,844 for the last year. Purchase of equipment was $654,197 compared to $507,788 for the last year.

Rockwell Medical, Inc., Q4 2013 Earnings Call, Feb 26, 2014

Rockwell Medical, Inc., Q4 2013 Earnings Call, Feb 26, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMTI:US $10.67 USD +0.32

RMTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $37.97 USD +0.23
Fresenius Medical Care AG & Co KGaA €48.63 EUR -0.64
View Industry Companies
 

Industry Analysis

RMTI

Industry Average

Valuation RMTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book 697.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCKWELL MEDICAL INC, please visit www.rockwellmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.